vTv Therapeutics (VTVT) investor relations material

Introduction and agenda

• Virtual event covered hypoglycemia burden in T1D, lived experience and market research, cadisegliatin’s mechanism and Phase 2 evidence, CATT1, and corporate updates.

• Guest clinicians and advocates spoke independently; their views were their own. Opening remarks included a forward-looking-statement notice.

KOL background and credentials

• Schafer Boeder is a board-certified endocrinologist, Medical Director at Paradigm Clinical Research, and Associate Professor of Medicine at UC San Diego.

• Klara Klein is an Assistant Professor at UNC Chapel Hill and directs its Endocrinology, Diabetes, and Obesity Clinical Research Unit.

• Cellist Alisa Weilerstein has lived with T1D since age nine and discussed managing it alongside international performance and parenting young children.

Market insights and analysis

• T1D affects ~2.1M people in the U.S. and 9.5M globally; global prevalence is projected to reach 14.7M by 2040, and most people with T1D are adults.

• ~75% of U.S. adults with T1D do not reach HbA1c <7; ~60% use multiple daily injections and ~40% use pumps or AID. No oral FDA-approved T1D adjunct was identified.

• A 2025 U.S. adult T1D survey found 65% had at least one clinically meaningful hypoglycemia burden; the weighted estimate among AID users was 54%.

• In separate surveys, 88% said they hate low glucose; 43% said fear of hypoglycemia impeded optimal glucose levels, and this group had 0.48% higher adjusted average A1C.

• Among surveyed endocrinologists, 85% ranked short-term hypoglycemia risk equally or above long-term hyperglycemia risk; 84%–96% would likely or definitely recommend a hypothetical adjunct that reduced lows without compromising HbA1c, assuming tolerability and coverage.